Why the study?
Mutations may impact DMD genetic diagnosis pipelines across different ethnicities.
Answers are grounded in this paper and cite their sources.
Ethnicity may orient genetic diagnosis flowcharts for DMD/BMD, impacting drug eligibility based on mutation type frequency.
OBJECTIVE: mutations, which may impact on DMD genetic diagnosis pipelines, we studied 328 patients with DMD and BMD from non-European countries. METHODS: gene modifiers. RESULTS: deletions and small mutations and its adoption could allow a detection rate close to 90% of all occurring mutations. Gene modifiers haplotypes were identified with some ethnic-specific configurations. CONCLUSIONS: Our data provide unreported mutation landscapes in different countries, suggesting that ethnicity may orient genetic diagnosis flowchart, which can be adjusted depending on the mutation type frequency, with impact in drug eligibility.
No takes yet. Share an insight, caveat, or question.
Selvatici et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: